Key result
NIP-121 was approximately 10 times more potent than cromakalim in shortening action potential duration and decreasing contractile force in isolated guinea pig ventricular myocardium.
Why the study?
Does NIP-121 shorten action potential duration and decrease contractile force compared to cromakalim in isolated guinea pig ventricular myocardium?
Does NIP-121 shorten action potential duration and decrease contractile force compared to cromakalim in isolated guinea pig ventricular myocardium?
NIP-121 is a novel potassium channel opener that is approximately 10 times more potent than cromakalim in altering cardiac action potential and contractility in preclinical models.
Answers are grounded in this paper and cite their sources.
No immediate clinical implications; leaves open translation of NIP-121 potency from guinea pig models.
The potencies of NIP-121, a new potassium channel opener, to shorten action potential duration and to decrease the contractile force was examined using isolated guinea pig right ventricular free wall and papillary muscle preparations, respectively; and they were compared with those of cromakalim. NIP-121 was about 10 times more potent than cromakalim with respect to both effects. This potency ratio in cardiac muscle was about the same as that observed in rat aorta and portal vein. These cardiac effects of both agents were antagonized by glibenclamide.
No takes yet. Share an insight, caveat, or question.
Shigenobu et al. (1991) studied this question. NIP-121 vs. cromakalim was evaluated on Action potential duration shortening and contractile force decrease. NIP-121 was approximately 10 times more potent than cromakalim in shortening action potential duration and decreasing contractile force in isolated guinea pig ventricular myocardium.
Synapse has enriched 10 related papers. Consider them for comparative context: